These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12080220)

  • 1. The economic impact of irritable bowel syndrome in a managed care setting.
    Patel RP; Petitta A; Fogel R; Peterson E; Zarowitz BJ
    J Clin Gastroenterol; 2002 Jul; 35(1):14-20. PubMed ID: 12080220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of care for irritable bowel syndrome patients in a health maintenance organization.
    Levy RL; Von Korff M; Whitehead WE; Stang P; Saunders K; Jhingran P; Barghout V; Feld AD
    Am J Gastroenterol; 2001 Nov; 96(11):3122-9. PubMed ID: 11721759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic consequences of irritable bowel syndrome: a US employer perspective.
    Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
    Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical costs in community subjects with irritable bowel syndrome.
    Talley NJ; Gabriel SE; Harmsen WS; Zinsmeister AR; Evans RW
    Gastroenterology; 1995 Dec; 109(6):1736-41. PubMed ID: 7498636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.
    Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C
    J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic burden of irritable bowel syndrome in Canada.
    Bentkover JD; Field C; Greene EM; Plourde V; Casciano JP
    Can J Gastroenterol; 1999 Mar; 13 Suppl A():89A-96A. PubMed ID: 10202215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective.
    Longstreth GF; Wilson A; Knight K; Wong J; Chiou CF; Barghout V; Frech F; Ofman JJ
    Am J Gastroenterol; 2003 Mar; 98(3):600-7. PubMed ID: 12650794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting.
    Akehurst RL; Brazier JE; Mathers N; O'Keefe C; Kaltenthaler E; Morgan A; Platts M; Walters SJ
    Pharmacoeconomics; 2002; 20(7):455-62. PubMed ID: 12093301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
    Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
    J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of irritable bowel syndrome in China.
    Zhang F; Xiang W; Li CY; Li SC
    World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria.
    Badia X; Mearin F; Balboa A; Baró E; Caldwell E; Cucala M; Díaz-Rubio M; Fueyo A; Ponce J; Roset M; Talley NJ
    Pharmacoeconomics; 2002; 20(11):749-58. PubMed ID: 12201794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and care of irritable bowel syndrome in a community-based population.
    Yawn BP; Locke GR; Lydick E; Wollan PC; Bertram SL; Kurland MJ
    Am J Manag Care; 2001 Jun; 7(6):585-92. PubMed ID: 11439732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice.
    Johansson PA; Farup PG; Bracco A; Vandvik PO
    BMC Gastroenterol; 2010 Mar; 10():31. PubMed ID: 20233451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Socioeconomic impact of irritable bowel syndrome in Canada.
    Boivin M
    Can J Gastroenterol; 2001 Oct; 15 Suppl B():8B-11B. PubMed ID: 11694908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health care utilization and economic issues in irritable bowel syndrome.
    Gralnek IM
    Eur J Surg Suppl; 1998; (583):73-6. PubMed ID: 10027677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of irritable bowel syndrome in the UK and US.
    Maxion-Bergemann S; Thielecke F; Abel F; Bergemann R
    Pharmacoeconomics; 2006; 24(1):21-37. PubMed ID: 16445300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
    Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
    BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Irritable bowel syndrome and healthcare consumption. An observational study in private gastroenterology].
    Dapoigny M; Dyard F; Grimaud JC; Guyot P; van Ganse E
    Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):265-71. PubMed ID: 12700510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
    Wu EQ; Forsythe A; Guérin A; Yu AP; Latremouille-Viau D; Tsaneva M
    Am J Ther; 2012 Nov; 19(6):e157-66. PubMed ID: 21317625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.